Ramsay R, Albreht A
J Neural Transm (Vienna). 2018; 125(11):1659-1683.
PMID: 29516165
DOI: 10.1007/s00702-018-1861-9.
Rudorfer M, Potter W
CNS Drugs. 2016; 7(4):273-312.
PMID: 27520753
DOI: 10.2165/00023210-199707040-00003.
Frieling H, Bleich S
Eur Arch Psychiatry Clin Neurosci. 2006; 256(5):268-73.
PMID: 16927039
DOI: 10.1007/s00406-006-0660-8.
Weber-Grandke H, Hahn G, Mutschler E, Mohrke W, Langguth P, Spahn-Langguth H
Br J Clin Pharmacol. 1993; 36(4):363-5.
PMID: 12959316
PMC: 1364691.
DOI: 10.1111/j.1365-2125.1993.tb00377.x.
Baker G, Coutts R, Greenshaw A
J Psychiatry Neurosci. 2000; 25(5):481-96.
PMID: 11109299
PMC: 1408023.
Metabolism of monoamine oxidase inhibitors.
Baker G, Urichuk L, McKenna K, Kennedy S
Cell Mol Neurobiol. 1999; 19(3):411-26.
PMID: 10319194
PMC: 11545467.
DOI: 10.1023/a:1006901900106.
Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug.
Reynolds G, Riederer P, Sandler M
J R Soc Med. 1981; 74(9):649-52.
PMID: 7288807
PMC: 1438868.
DOI: 10.1177/014107688107400905.
Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers.
Bieck P, Antonin K
Eur J Clin Pharmacol. 1982; 22(4):301-8.
PMID: 7106165
DOI: 10.1007/BF00548397.
Tranylcypromine isomers: single-dose effects in normal human subjects.
Gorenstein C, Gentil V
Psychopharmacology (Berl). 1981; 75(4):400-3.
PMID: 6803288
DOI: 10.1007/BF00435862.
Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A.
Waldmeier P, Antonin K, Feldtrauer J, Grunenwald C, Paul E, Lauber J
Eur J Clin Pharmacol. 1983; 25(3):361-8.
PMID: 6628524
DOI: 10.1007/BF01037949.
Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS.
Lauber J, Waldmeier P
J Neural Transm. 1984; 60(3-4):247-64.
PMID: 6527139
DOI: 10.1007/BF01249097.
Neurochemical and neuropharmacological properties of 4-fluorotranylcypromine.
Coutts R, Rao T, Baker G, Micetich R, Hall T
Cell Mol Neurobiol. 1987; 7(3):271-90.
PMID: 3440283
PMC: 11567413.
DOI: 10.1007/BF00711304.
Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.
Baker G, Coutts R, McKenna K
J Psychiatry Neurosci. 1992; 17(5):206-14.
PMID: 1362653
PMC: 1188458.